Cell-Based Phenotypic Screen for Antifibrotic Compounds Targets Eicosanoid Metabolism
Circulation Research · 2023
DOI: 10.1161/circresaha.122.322272 ↗Kurz gefasst
Editorial in der Zeitschrift Circulation Research, 2023. Verfasst von Janet K Lighthouse und 1 weiteren Autor:innen. Beteiligte Einrichtung: Wegmans School of Pharmacy, Department of Pharmaceutical Sciences, St. John Fisher University, Rochester, NY (J.K.L.). Hauptthemen laut MEDLINE: Myocardium, Eicosanoids. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Cardiac fibroblasts produce extracellular matrix (ECM) in response to a range of pathological insults including pressure overload, humoral stimulation, or myocardial infarction (MI).While ECM deposition initially preserves the structural integrity of the heart, unchecked fibroblast activation eventually leads to the development of pathological fibrosis 1 .Fibrosis increases the rigidity of ventricular muscle and is linked to the pathogenesis of both HFrEF (heart failure with reduced ejection fraction), and HFpEF (heart failure with preserved ejection fraction), with the latter projected to become the predominate form of all HF cases 2 .Because of the complex etiology of the disease, and the potential causative association with metabolic disorders, inflammation, and fibrosis, HFpEF is typically less responsive than HFrEF to existing treatments targeting the renin angiotensin system (RAS) and beta adrenergic signaling 2 .Potentially promising HFpEF treatments include mineralcorticoid receptor antagonists such as spironolactone and eplerenone, and SGLT2i, which reduce inflammation and PKG oxidation to provide cardiovascular benefits 2, 3 .Indeed, the evidence that maintaining PKG signaling is cardioprotective has been supported in various models and is thought to include phosphorylation and activation of ERK1/2 to limit fibroblast activation and ECM secretion 4 .However, interventions that target fibrosis remain an unmet goal in the control and treatment of HFpEF.Indeed, only two FDA approved therapeutics exist that directly limit fibrosis, nintedanib and pirfenidone.Unfortunately, nintedanib is contraindicated for treatment of heart disease due to increased incident rate
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wegmans School of Pharmacy, Department of Pharmaceutical Sciences, St. John Fisher University, Rochester, NY (J.K.L.).
- Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, NY (J.K.L., E.M.S.).
- Department of Medicine (E.M.S.), University of Rochester, NY.
- Department of Pharmacology and Physiology (E.M.S.), University of Rochester, NY.
- School of Medicine and Dentistry, and Department of Biomedical Engineering (E.M.S.), University of Rochester, NY.
ORCID-Profile: Janet K Lighthouse, Eric M Small
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Lighthouse, J. K., & Small, E. M. (2023). Cell-Based Phenotypic Screen for Antifibrotic Compounds Targets Eicosanoid Metabolism. Circulation Research. https://doi.org/10.1161/circresaha.122.322272
Vancouver
Lighthouse JK, Small EM. Cell-Based Phenotypic Screen for Antifibrotic Compounds Targets Eicosanoid Metabolism. Circulation Research. 2023. doi:10.1161/circresaha.122.322272
BibTeX
@article{Lighthouse2023,
author = {Lighthouse, Janet K and Small, Eric M},
title = {Cell-Based Phenotypic Screen for Antifibrotic Compounds Targets Eicosanoid Metabolism},
journal = {Circulation Research},
year = {2023},
doi = {10.1161/circresaha.122.322272}
}
EUVIMED